Noindex: medium evidence

1120-02-1

CAS 1120-02-1

1120-02-1 (CAS 1120-02-1) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
1120-02-1
CAS Number
1120-02-1
UNII
BPW1DD4IZ8
InChIKey
SZEMGTQCPRNXEG-UHFFFAOYSA-M
ChEMBL ID
CHEMBL109458
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- IC50 3150 nM 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 1120-02-1 used for in pharmaceutical contexts?

1120-02-1 (CAS 1120-02-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 1120-02-1?

No adverse-event association or SIDER side-effect rows are rendered for 1120-02-1 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 1120-02-1 also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for 1120-02-1.

What clinical phase is 1120-02-1 in?

No phase 1-4 clinical development badge is rendered for 1120-02-1 because the matched compound identifier rows do not contain a max-phase value.